IOBT -
IO Biotech, Inc. Common Stock
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
0.66 0.0 (-0.62%) |
--- |
0.0 (-0.03%) |
-0.01 (-1.48%) |
0.04 (5.37%) |
0.0 (-0.62%) |
-0.03 (-4.29%) |
-0.03 (-4.29%) |
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Earnings & Ratios
- Basic EPS:
- -0.4
- Diluted EPS:
- -0.4
- Basic P/E:
- -1.6503
- Diluted P/E:
- -1.6503
- RSI(14) 1m:
- 0.0
- VWAP:
- 0.66
- RVol:
Events
Period |
Kind |
Movement |
Occurred At |
Related News
Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Oct 14, 2025 17:00
Nasdaq Jumps 150 Points; US Pending Home Sales Rise
Sep 29, 2025 14:11
TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Sep 23, 2025 17:00
Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
Aug 26, 2025 17:00
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
Apr 26, 2025 19:05
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
Feb 23, 2025 17:07
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
Nov 07, 2024 15:00
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Sep 14, 2024 06:30
IO Biotech to Present at Jefferies Global Healthcare Conference
May 23, 2024 12:30
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 14, 2024 11:55